Bivalirudin Monitoring in Pediatric Ventricular Assist Device and Extracorporeal Membrane Oxygenation: Analysis of Single-Center Retrospective Cohort Data 2018-2022

Engel ER, Perry T, Block M, Palumbo JS, Lorts A, Luchtman-Jones L (2024) · Pediatric Critical Care Medicine · n=22

RCT evidence detailTrial reference

GRADE LowCohort / case seriesCondition: Venous Congestion in Surgical Flaps →

This trial (highlighted) by sample size alongside other indexed Venous Congestion in Surgical Flaps trials. Larger trials generally carry more statistical weight.

Study Profile

Design: single-center retrospective laboratory validation study (Cincinnati Children's Hospital Medical Center, 2018-2022) - 115 VAD samples and 105 ECMO samples assessed
Sample size (n): 22
Intervention: Bivalirudin-calibrated dilute thrombin time (Bival dTT) assay for anticoagulation monitoring in pediatric VAD and ECMO
Comparator: Standard activated partial thromboplastin time (aPTT) assay
Primary endpoint: Correlation between Bival dTT, dTT, and aPTT vs bivalirudin plasma concentrations
Primary result: Bival dTT excellent correlation with dTT (R²=0.86-0.87) and anti-IIa (R²=0.94); aPTT correlated poorly (R²=0.004-0.1); Bival dTT validated for clinical use
Follow-up duration: VAD/ECMO support duration
PMID: 38713010

Key Findings

aPTT correlates poorly with bivalirudin anticoagulant effect (R²=0.004-0.1)
Bival dTT and dTT show excellent correlation with anti-IIa (R²=0.86-0.94)
Provides validated alternative to aPTT for pediatric MCS monitoring
Single institution can validate and clinically implement
Opportunity for inter-institutional standardization

Limitations

Single-center retrospective design
Small patient cohort (n=22)
No correlation with clinical outcomes yet established
Therapeutic range still requires determination
Not applicable to whole-leech hirudotherapy

Clinical Implications

Engel 2024 addresses a critical laboratory monitoring gap for bivalirudin in pediatric mechanical circulatory support. For ASH, this work demonstrates the technical infrastructure required to safely deploy the synthetic thrombin inhibitor pharmaceutical pathway - sophisticated assays, single-institution validation, inter-institution standardization - structurally separate from the K040187 device-leech US clinical practice which requires no such monitoring infrastructure.

Related Trials

Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation

McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)

Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support

Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)

Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation

Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022)

Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review

Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)

← Back to RCT Library